Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Riluzole

Known as: 2-Amino-6-trifluoromethoxybenzothiazole, 2 Amino 6 trifluoromethoxybenzothiazole, 2-Amino-6-(trifluoromethoxy)benzothiazole 
A benzothiazole derivative with neuroprotective and potential anti-depressant and anxiolytic activities. While the mechanism of action of riluzole is… Expand
National Institutes of Health

Related topics

Related topics

22 relations
Amyotrophic Lateral SclerosisBenzothiazolesHypersensitivityIn Blood
Expand

Broader (5)

AnestheticsAnticonvulsantsExcitatory Amino Acid AntagonistsNeuroprotective Agents
Expand

Narrower (4)

Impax Brand of RiluzolePK-26124RP-54274Rilutek

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal… Expand
Review
2019
Review
2019
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Mood disorders represent the largest cause of disability worldwide. The monoaminergic deficiency hypothesis, which has dominated… Expand
Review
2019
Review
2019
Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
&NA; Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathological… Expand
  • figure 1
Review
2018
Review
2018
Time is spine: a review of translational advances in spinal cord injury.
Acute traumatic spinal cord injury (SCI) is a devastating event with far-reaching physical, emotional, and economic consequences… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Review
2018
Review
2018
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics
The recent approval of edaravone has provided an intravenous option to treat amyotrophic lateral sclerosis (ALS) in addition to… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • table 2
Highly Cited
1996
Highly Cited
1996
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Abstract Summary Background Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
1996
Highly Cited
1996
Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis
Familial amyotrophic lateral sclerosis (FALS) has been linked in some families to dominant mutations of the SOD1 gene encoding Cu… Expand
Review
1996
Review
1996
The pharmacology and mechanism of action of riluzole
  • A. Doble
  • Neurology
  • 1996
    • Corpus ID: 19112952
The excitotoxic hypothesis of neurodegeneration has stimulated much interest in the possibility of using compounds that will… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1996
Highly Cited
1996
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
BACKGROUND Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an initial study… Expand
Highly Cited
1994
Highly Cited
1994
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
BACKGROUND Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE